Fig. 5
B12 decreases tumor burden and delays T-cell leukemia progression in vivo. a Treatment and analysis scheme. Rag1−/− mice (females, n = 5 per group) were injected with 5 × 106 D1mutP2 cells via lateral tail vein injection. A day later mice were randomly distributed and injected with 250 μg B12 via the same route. PBS was used as the vehicle control. Injections were administered every 7 days. At day 15, a group of mice were killed and tumor burden in various organs was analyzed, while in another group treatment continued and survival was monitored. b Percentage of leukemic cells in the indicated organs was analyzed using flow cytometry, wherein the percentage of GFP-positive leukemia cells within the live cell population was considered as the leukemia burden. c Analysis of spleen size. Frequency of d NK and e macrophage cell infiltration into the indicated organs was analyzed by flow cytometry. Statistical analysis was performed by unpaired t test (***p < 0.001, **p < 0.01, *p < 0.05). f Kaplan–Meier survival curves of mice treated with vehicle (median survival 16 days) or B12 (median survival 21 days). Statistical analysis was performed using the Log-Rank (Mantel–Cox) test. g Experimental scheme for treatment starting at day 7 post-transplantation, when leukemia cells are already clearly detected in the blood. h Kaplan–Meier survival curves of mice treated with vehicle (median survival 17 days) or B12 (median survival 19 days). Statistical analysis was performed using the Log-Rank (Mantel–Cox) test
